Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Hong Qin
Beckman Research Institute/city of Hope, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Innolifes, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Innolifes, Inc. is an alternative and complementary ingredient and raw material manufacturer of pharmaceuticals, herbal/botanical extracts, nutritional supplements, food & beverages and cosmetics. Dr. Qin is the Principal Investigator on the funded research grant that proposes to develop a therapeutic novel antibody specific for a B-cell tumor associated marker that has not been clinically targeted. Given that the project aims of the grant, in part, are to investigate the therapeutic potential of BAFF-R mAb in relapsed B-cell malignancies resistant to CD19-targeted treatments and humanize BAFF-R mAbs and validate the lead candidate and that the NIH-funded trial results could affect Dr. Qin’s interests in Innolifes, Inc., the interests were determined to be related.
Translation development of a novel therapeutic antibody against drug-resistant B-cell malignancies
Project Narrative Targeted immunotherapies against B-cell malignancies is hindered by emerging drug resistance, thus creating an urgent need. We hypothesize that B-cell activating factor-receptor (BAFF-R) is a suitable alternative therapeutic antibody target for B-cell lymphomas and leukemias and will test this with our previously developed anti-BAFF-R chimeric antibodies by two specific aims: 1) Investigate the therapeutic potential of BAFF-R antibodies in relapsed B-cell malignancies resistant to CD19-targeted treatments; and 2) Humanize BAFF-R antibodies and validate lead candidates in vivo. Success in these studies will support a first-in-human clinical trial of a novel therapeutic antibody to address unmet clinical needs.
Filed on April 29, 2019.
Tell us what you know about Hong Qin's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Hong Qin filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Hong Qin | Beckman Research Institute/city of Hope | Conflict of Interest | Pepromene Bio, Inc. | $60,000 - $79,999 |
| Hong Qin | Beckman Research Institute/city of Hope | Conflict of Interest | Innolifes, Inc. | $20,000 - $39,999 |
| Hong Qin | Beckman Research Institute/city of Hope | Conflict of Interest | Pepromene Bio, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.